Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury

Philip E. Empey, Nieves Velez De Mendizabal, Michael J. Bell, Robert Bies, Kacey B. Anderson, Patrick M. Kochanek, P. David Adelson, Samuel M. Poloyac

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: Preclinical and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic injury, may also lead to drug toxicity that may limit its benefit. Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that drug levels are elevated. Fosphenytoin is metabolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic medication. The objective of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmacokinetics in children with severe traumatic brain injury. Design: Pharmacokinetic analysis of subjects participating in a multicenter randomized phase III study of therapeutic hypothermia for severe traumatic brain injury. Setting: ICU at the Children's Hospital of Pittsburgh. Patients: Nineteen children with severe traumatic brain injury. Interventions: None. Measurements and Main Results: A sum of 121 total and 114 free phenytoin levels were evaluated retrospectively in 10 hypothermia-treated and nine normothermia-treated children who were randomized to 48 hours of cooling to 32-33 C followed by slow rewarming or controlled normothermia. Drug dosing, body temperatures, and demographics were collected during cooling, rewarming, and posttreatment periods (8 d). A trend toward elevated free phenytoin levels in the hypothermia group (p = 0.051) to a median of 2.2 mg/L during rewarming was observed and was not explained by dosing differences. Nonlinear mixed-effects modeling incorporating both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-variant component of the maximum velocity of phenytoin metabolism (Vmax) 4.6-fold (11.6-2.53 mg/hr) and reduced the overall Vmax by ~ 50%. Simulations showed that the increased risk for drug toxicity extends many days beyond the end of the cooling period. Conclusions: Therapeutic hypothermia significantly reduces phenytoin elimination in children with severe traumatic brain injury leading to increased drug levels for an extended period of time after cooling. Pharmacokinetic interactions between hypothermia and medications should be considered when caring for children receiving this therapy.

Original languageEnglish
Pages (from-to)2379-2387
Number of pages9
JournalCritical Care Medicine
Volume41
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Induced Hypothermia
Phenytoin
Rewarming
Hypothermia
Pharmacokinetics
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Nervous System Trauma
Body Temperature
Anticonvulsants
Traumatic Brain Injury
Demography
Therapeutics

Keywords

  • children
  • drug metabolism
  • hypothermia
  • pharmacokinetics
  • phenytoin
  • traumatic brain injury

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Empey, P. E., De Mendizabal, N. V., Bell, M. J., Bies, R., Anderson, K. B., Kochanek, P. M., ... Poloyac, S. M. (2013). Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Critical Care Medicine, 41(10), 2379-2387. https://doi.org/10.1097/CCM.0b013e318292316c

Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. / Empey, Philip E.; De Mendizabal, Nieves Velez; Bell, Michael J.; Bies, Robert; Anderson, Kacey B.; Kochanek, Patrick M.; Adelson, P. David; Poloyac, Samuel M.

In: Critical Care Medicine, Vol. 41, No. 10, 10.2013, p. 2379-2387.

Research output: Contribution to journalArticle

Empey, PE, De Mendizabal, NV, Bell, MJ, Bies, R, Anderson, KB, Kochanek, PM, Adelson, PD & Poloyac, SM 2013, 'Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury', Critical Care Medicine, vol. 41, no. 10, pp. 2379-2387. https://doi.org/10.1097/CCM.0b013e318292316c
Empey, Philip E. ; De Mendizabal, Nieves Velez ; Bell, Michael J. ; Bies, Robert ; Anderson, Kacey B. ; Kochanek, Patrick M. ; Adelson, P. David ; Poloyac, Samuel M. / Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. In: Critical Care Medicine. 2013 ; Vol. 41, No. 10. pp. 2379-2387.
@article{d80a46c65eca429dab3705086f4ea589,
title = "Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury",
abstract = "Objective: Preclinical and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic injury, may also lead to drug toxicity that may limit its benefit. Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that drug levels are elevated. Fosphenytoin is metabolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic medication. The objective of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmacokinetics in children with severe traumatic brain injury. Design: Pharmacokinetic analysis of subjects participating in a multicenter randomized phase III study of therapeutic hypothermia for severe traumatic brain injury. Setting: ICU at the Children's Hospital of Pittsburgh. Patients: Nineteen children with severe traumatic brain injury. Interventions: None. Measurements and Main Results: A sum of 121 total and 114 free phenytoin levels were evaluated retrospectively in 10 hypothermia-treated and nine normothermia-treated children who were randomized to 48 hours of cooling to 32-33 C followed by slow rewarming or controlled normothermia. Drug dosing, body temperatures, and demographics were collected during cooling, rewarming, and posttreatment periods (8 d). A trend toward elevated free phenytoin levels in the hypothermia group (p = 0.051) to a median of 2.2 mg/L during rewarming was observed and was not explained by dosing differences. Nonlinear mixed-effects modeling incorporating both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-variant component of the maximum velocity of phenytoin metabolism (Vmax) 4.6-fold (11.6-2.53 mg/hr) and reduced the overall Vmax by ~ 50{\%}. Simulations showed that the increased risk for drug toxicity extends many days beyond the end of the cooling period. Conclusions: Therapeutic hypothermia significantly reduces phenytoin elimination in children with severe traumatic brain injury leading to increased drug levels for an extended period of time after cooling. Pharmacokinetic interactions between hypothermia and medications should be considered when caring for children receiving this therapy.",
keywords = "children, drug metabolism, hypothermia, pharmacokinetics, phenytoin, traumatic brain injury",
author = "Empey, {Philip E.} and {De Mendizabal}, {Nieves Velez} and Bell, {Michael J.} and Robert Bies and Anderson, {Kacey B.} and Kochanek, {Patrick M.} and Adelson, {P. David} and Poloyac, {Samuel M.}",
year = "2013",
month = "10",
doi = "10.1097/CCM.0b013e318292316c",
language = "English",
volume = "41",
pages = "2379--2387",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury

AU - Empey, Philip E.

AU - De Mendizabal, Nieves Velez

AU - Bell, Michael J.

AU - Bies, Robert

AU - Anderson, Kacey B.

AU - Kochanek, Patrick M.

AU - Adelson, P. David

AU - Poloyac, Samuel M.

PY - 2013/10

Y1 - 2013/10

N2 - Objective: Preclinical and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic injury, may also lead to drug toxicity that may limit its benefit. Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that drug levels are elevated. Fosphenytoin is metabolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic medication. The objective of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmacokinetics in children with severe traumatic brain injury. Design: Pharmacokinetic analysis of subjects participating in a multicenter randomized phase III study of therapeutic hypothermia for severe traumatic brain injury. Setting: ICU at the Children's Hospital of Pittsburgh. Patients: Nineteen children with severe traumatic brain injury. Interventions: None. Measurements and Main Results: A sum of 121 total and 114 free phenytoin levels were evaluated retrospectively in 10 hypothermia-treated and nine normothermia-treated children who were randomized to 48 hours of cooling to 32-33 C followed by slow rewarming or controlled normothermia. Drug dosing, body temperatures, and demographics were collected during cooling, rewarming, and posttreatment periods (8 d). A trend toward elevated free phenytoin levels in the hypothermia group (p = 0.051) to a median of 2.2 mg/L during rewarming was observed and was not explained by dosing differences. Nonlinear mixed-effects modeling incorporating both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-variant component of the maximum velocity of phenytoin metabolism (Vmax) 4.6-fold (11.6-2.53 mg/hr) and reduced the overall Vmax by ~ 50%. Simulations showed that the increased risk for drug toxicity extends many days beyond the end of the cooling period. Conclusions: Therapeutic hypothermia significantly reduces phenytoin elimination in children with severe traumatic brain injury leading to increased drug levels for an extended period of time after cooling. Pharmacokinetic interactions between hypothermia and medications should be considered when caring for children receiving this therapy.

AB - Objective: Preclinical and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic injury, may also lead to drug toxicity that may limit its benefit. Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that drug levels are elevated. Fosphenytoin is metabolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic medication. The objective of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmacokinetics in children with severe traumatic brain injury. Design: Pharmacokinetic analysis of subjects participating in a multicenter randomized phase III study of therapeutic hypothermia for severe traumatic brain injury. Setting: ICU at the Children's Hospital of Pittsburgh. Patients: Nineteen children with severe traumatic brain injury. Interventions: None. Measurements and Main Results: A sum of 121 total and 114 free phenytoin levels were evaluated retrospectively in 10 hypothermia-treated and nine normothermia-treated children who were randomized to 48 hours of cooling to 32-33 C followed by slow rewarming or controlled normothermia. Drug dosing, body temperatures, and demographics were collected during cooling, rewarming, and posttreatment periods (8 d). A trend toward elevated free phenytoin levels in the hypothermia group (p = 0.051) to a median of 2.2 mg/L during rewarming was observed and was not explained by dosing differences. Nonlinear mixed-effects modeling incorporating both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-variant component of the maximum velocity of phenytoin metabolism (Vmax) 4.6-fold (11.6-2.53 mg/hr) and reduced the overall Vmax by ~ 50%. Simulations showed that the increased risk for drug toxicity extends many days beyond the end of the cooling period. Conclusions: Therapeutic hypothermia significantly reduces phenytoin elimination in children with severe traumatic brain injury leading to increased drug levels for an extended period of time after cooling. Pharmacokinetic interactions between hypothermia and medications should be considered when caring for children receiving this therapy.

KW - children

KW - drug metabolism

KW - hypothermia

KW - pharmacokinetics

KW - phenytoin

KW - traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84884901595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884901595&partnerID=8YFLogxK

U2 - 10.1097/CCM.0b013e318292316c

DO - 10.1097/CCM.0b013e318292316c

M3 - Article

VL - 41

SP - 2379

EP - 2387

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 10

ER -